Comparative study of various intracervically administered PG gel preparations for termination of first trimester pregnancies.
In a randomized, double-blind study, 30 healthy, nulliparous women of similar gestational age were given intracervical applications of 0.5mg PGE2, 0.05mg Sulprostone or 0.1mg Sulprostone gel in order to soften the cervix prior to curettage for first trimester termination of pregnancy. The preparations were administered 8 hours before curettage. The number of complete and incomplete abortions, ease of passage through the cervical canal, as measured by a tonometer before and 8 hours after the administration of prostaglandin, the degree of pain experienced and the quantity of analgesics required, plus the frequency of systemic side effects were all always assessed by one trialist. With regard to the rate of abortion and cervical softening, the administration of 0.1mg Sulprostone gel proved the most effective method. However, in comparison with the others, it also caused the greatest degree of pain and necessitated the greatest use of analgesics. The softening effect of the prostaglandin E2 gel was significantly less and in this group there were two cases of cervical lesion due to tenaculum laceration. The intracervical application of 0.05mg Sulprostone gel is to be recommended for pre-operative ripening of the cervix before termination of pregnancy in the first trimester, as it effectively dilates the cervix and does not cause systemic side effects or pain in the lower abdomen, enough to make treatment necessary.
D000005:Abdomen; D000028:Abortion, Induced / Q000009:adverse effects; D002584:Cervix Uteri / Q000502:physiology; D002986:Clinical Trials as Topic; D004107:Dilatation and Curettage; D015232:Dinoprostone / Q000031:analogs & derivatives; D004311:Double-Blind Method; D005260:Female; D005782:Gels; D006801:Humans; D009120:Muscle Cramp / Q000209:etiology; D010149:Postoperative Pain / Q000209:etiology; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011458:Prostaglandins E / Q000008:administration & dosage*; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage; D014592:Uterine Hemorrhage / Q000209:etiology
D005782:Gels; D011458:Prostaglandins E; D011459:Prostaglandins E, Synthetic; C016767:sulprostone; D015232:Dinoprostone